As of today (2024-04-19), Affymax's share price is $0.0007.
Affymax's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2014 was $-0.22. Hence, Affymax's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Affymax's Price-to-Operating-Cash-Flow or its related term are showing as below:
Affymax's Cash Flow from Operations per share for the
three
months ended in Jun. 2014 was $-0.04.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2014 was $-0.22.
Affymax Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Affymax's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Affymax Annual Data
|
|
Trend |
Dec04 |
Dec05 |
Dec06 |
Dec07 |
Dec08 |
Dec09 |
Dec10 |
Dec11 |
Dec12 |
Dec13 |
| Price-to-Operating-Cash-Flow |
|
|
|
|
|
|
- |
- |
- |
- |
- |
|
Affymax Quarterly Data
|
|
Sep09 |
Dec09 |
Mar10 |
Jun10 |
Sep10 |
Dec10 |
Mar11 |
Jun11 |
Sep11 |
Dec11 |
Mar12 |
Jun12 |
Sep12 |
Dec12 |
Mar13 |
Jun13 |
Sep13 |
Dec13 |
Mar14 |
Jun14 |
| Price-to-Operating-Cash-Flow |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison
For the Biotechnology subindustry, Affymax's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Affymax Price-to-Operating-Cash-Flow Distribution
For the Biotechnology industry and Healthcare sector, Affymax's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Affymax's Price-to-Operating-Cash-Flow falls into.
Affymax Price-to-Operating-Cash-Flow Calculation
Affymax's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 0.0007 | / | -0.224 |
| = | |
Affymax's Share Price of today is $0.0007.
Affymax's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.22.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Affymax (Affymax) Business Description
Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.
Executives
| John Peter Walker |
director |
126 ISABELLA AVE, ATHERTON CA 94027 |
| John A Orwin |
director |
C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063 |
| Mark G Thompson |
officer: Chief Financial Officer |
8383 WILSHIRE BLVD BEVERLY HILLS CA 90211 |
| Jeffrey H Knapp |
officer: Chief Commercial Officer |
4001 MIRANDA AVE. PALO ALTO CA 94304 |
| Herb Cross |
officer: Chief Financial Officer |
3061 ZANKER RD, SAN JOSE CA 95134 |
| Anne-marie Duliege |
officer: Chief Medical Officer |
4001 MIRANDA AVENUE, PALO ALTO CA 94304 |
| Kathleen Laporte |
director |
|
| Karin L Walker |
officer: VP, Finance & CAO |
C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
| Heek Christi Van |
director |
4001 MIRANDA AVENUE, PALO ALTO CA 94304 |
| Daniel K Spiegelman |
director |
MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003 |
| Hollings Renton |
director |
|
| Keith R Leonard |
director |
ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
| Ted W Love |
director |
C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
| Paul B Cleveland |
officer: EVP, Corp. Development and CFO |
C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304 |
| Arlene Morris |
director, officer: CEO |
C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304 |
Affymax (Affymax) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AFFY has been successfully added to your